← boardnext 2026-07-30next 2026-08-10next 2026-09-01next 2026-09-28next 2026-10-19next 2026-11-05next 2027-01-01next 2027-01-13next 2027-03-27next 2027-04-13next 2027-04-30next 2027-06-01next 2027-07-27next 2027-07-30next 2027-09-23next 2027-09-28next 2028-02-01next 2028-02-29next 2028-03-14next 2028-08-18next 2028-10-09next 2030-05-24next 2031-01-17
INCY
Incyte Corporationdistress 0/10 · well-funded / low risk$115.390%today-3% from 52w high
Oncology 3Immunology / Inflammation 2
Lead: Solid Tumors
Revenue
$1273M
Liquidity
$3749M
Runway
—
Shares 1y
+2%
Price & events
+9.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.3%
1D
-1.1%
1W
+10.5%
1M
+20.9%
3M
+13.1%
6M
+63.2%
1Y
+75.4%
2Y
+45.5%
5Y
+33.5%
All
Overview
- Market Cap
- $23.05B
- Volume
- 46.62K
- 52 Week Range
- $67.38 – $119
- Total Shares
- 199.78M
- Float Shares
- 167.48M
- Short %
- 9.12%
- % Held by Insiders
- 1.89%
- % Held by Institutions
- 106.64%
- RVOL
- 0.03x
- Beta
- 0.76
Pipeline stages · 24 programs
INCB177054, Retifanlimab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Ruxolitinib, Capecitabine, Regorafenib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Tafasitamab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
INCB099280
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Povorcitinib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Parsaclisib, itacitinib, ruxolitinib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
INCB161734, Investigator's choice of chemotherapy
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
INCA33890, Bevacizumab, FOLFOX
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
INCB186748, Cetuximab, GEMNabP
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
INCB123667, Investigator's choice of chemotherapy
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Show all 24 programs · 14 more ▾
INCB057643, Ruxolitinib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Axatilimab, Ruxolitinib, Corticosteroids
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
INCB0123667, Palbociclib, Bevacizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
INCB000928
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
INCA000585
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
INCA034176, Best available Treatment (BAT)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Ponatinib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
INCA033989, Best Available Treatment
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
INCA035784
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
INCA036873
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
INCB160058, Standard disease-directed therapy
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
INCA036978, Standard disease-directed therapy
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Tacrolimus (Tac), Methotrexate (MTX), Ruxolitinib (Rux)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pemigatinib, Gemcitabine, Cisplatin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 46 trials · 40 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-07-30 Estimated 50% readout ~2026-09-13 final ~2027-01-31 | Phase 1/2 | INCB177054, Retifanlimab | Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors | — | active not recruiting |
| 2026-08-10 Estimated 50% readout ~2026-10-24 | Phase 3 | Ruxolitinib Cream, Vehicle Cream | NonSegmental Vitiligo | — | recruiting |
| 2026-09-01 Estimated 50% readout ~2026-11-15 | Phase 3 | Tafasitamab, Lenalidomide, Rituximab | Diffuse Large B-cell Lymphoma | — | active not recruiting |
| 2026-09-28 Estimated 50% readout ~2026-11-12 | Phase 2 | INCB099280 | Cutaneous Squamous Cell Carcinoma | — | active not recruiting |
| 2026-10-09 Estimated 50% readout ~2026-12-23 | Phase 3 | Ruxolitinib Cream, Vehicle Cream | Hidradenitis Suppurativa | — | recruiting |
Show all 46 trials · 41 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-10-09 Estimated 50% readout ~2026-12-23 | Phase 3 | Ruxolitinib Cream, Vehicle Cream | Hidradenitis Suppurativa | — | recruiting |
| 2026-10-19 Estimated 50% readout ~2027-01-02 | Phase 3 | Povorcitinib | Prurigo Nodularis | — | active not recruiting |
| 2026-10-19 Estimated 50% readout ~2027-01-02 | Phase 3 | Povorcitinib | Prurigo Nodularis | — | active not recruiting |
| 2026-11-05 Estimated 50% readout ~2026-12-20 | Phase 2 | Parsaclisib, itacitinib, ruxolitinib | B-Cell Malignancies | — | active not recruiting |
| 2026-12-26 Estimated 50% readout ~2027-03-11 | Phase 3 | Povorcitinib | Hidradenitis Suppurativa (HS) | — | active not recruiting |
| 2027-01-01 Estimated 50% readout ~2027-01-31 | Phase 1 | INCB161734, Cetuximab, Retifanlimab | Solid Tumors | — | recruiting |
| 2027-01-13 Estimated 50% readout ~2027-02-12 | Phase 1 | INCA33890, bevacizumab, FOLFIRI | Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors | — | recruiting |
| 2027-03-27 Estimated 50% readout ~2027-04-26 | Phase 1 | INCB186748, Cetuximab, GEMNabP | Solid Tumors | — | active not recruiting |
| 2027-04-13 Estimated 50% readout ~2027-05-13 | Phase 1 | INCB123667 | Hepatic Insufficiency, Liver Diseases | — | recruiting |
| 2027-04-27 Estimated 50% readout ~2027-06-11 | Phase 2 | INCB123667 | Ovarian Cancer | — | recruiting |
| 2027-04-30 Estimated 50% readout ~2027-07-14 | Phase 3 | Ruxolitinib Cream, Vehicle Cream | NonSegmental Vitiligo | — | recruiting |
| 2027-04-30 Estimated 50% readout ~2027-05-30 | Phase 1 | INCB057643, Ruxolitinib | Myelofibrosis, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome, Myeloproliferative Neoplasm, Relapsed or Refractory Primary Myelofibrosis, Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis), ET (Essential Thrombocythemia) | — | active not recruiting |
| 2027-06-01 Estimated 50% readout ~2027-07-16 | Phase 2 | Axatilimab, Ruxolitinib, Corticosteroids | Chronic Graft-versus-host-disease | — | active not recruiting |
| 2027-07-27 Estimated 50% readout ~2027-08-26 | Phase 1 | INCB0123667, Palbociclib, Bevacizumab | Solid Tumors | — | recruiting |
| 2027-07-30 Estimated 50% readout ~2027-09-13 | Phase 2 | INCB000928 | Fibrodysplasia Ossificans Progressiva (FOP) | — | recruiting |
| 2027-08-29 Estimated 50% readout ~2027-10-13 | Phase 2 | Tafasitamab | Hematologic Malignancies | — | recruiting |
| 2027-09-23 Estimated 50% readout ~2027-11-07 | Phase 2 | INCA000585 | Immune Thrombocytopenia | — | recruiting |
| 2027-09-28 Estimated 50% readout ~2027-12-12 | Phase 3 | INCA034176, Corticosteroids | Chronic Graft-versus-host-disease | — | recruiting |
| 2027-09-30 Estimated 50% readout ~2027-11-14 | Phase 2 | Ruxolitinib, Capecitabine, Regorafenib | Pancreatic Cancer, Colorectal Cancer (CRC), Breast Cancer, Lung Cancer | — | active not recruiting |
| 2028-02-01 Estimated 50% readout ~2028-03-17 | Phase 1/2 | Ponatinib | Acute Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia, Blast Phase Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Leukemia, Lymphoma, Solid Tumors | — | recruiting |
| 2028-02-28 Estimated 50% readout ~2028-05-13 | Phase 3 | povorcitinib | Hidradenitis Suppurativa (HS) | — | recruiting |
| 2028-02-29 Estimated 50% readout ~2028-03-30 | Phase 1 | INCA033989, Ruxolitinib | Myeloproliferative Neoplasms | — | recruiting |
| 2028-03-14 Estimated 50% readout ~2028-04-13 | Phase 1 | INCA035784 | Myeloproliferative Neoplasms | — | recruiting |
| 2028-03-25 Estimated 50% readout ~2028-05-09 | Phase 2 | Povorcitinib | Hidradenitis Suppurativa (HS) | — | recruiting |
| 2028-05-31 Estimated 50% readout ~2028-08-14 | Phase 3 | INCA034176, Best Available Therapy (BAT) | Chronic Graft-versus-host-disease | — | active not recruiting |
| 2028-08-18 Estimated 50% readout ~2028-09-17 | Phase 1 | INCA036873 | Solid Tumors, Hematologic Malignancies | — | recruiting |
| 2028-09-15 Estimated 50% readout ~2028-11-29 | Phase 3 | INCB161734, Investigator's choice of chemotherapy | Solid Tumors | — | recruiting |
| 2028-10-09 Estimated 50% readout ~2028-11-08 | Phase 1 | INCB160058, Standard disease-directed therapy | Myeloproliferative Neoplasms | — | recruiting |
| 2028-10-29 Estimated 50% readout ~2028-11-28 | Phase 1 | INCA033989, Ruxolitinib | Myeloproliferative Neoplasms | — | recruiting |
| 2028-11-15 Estimated 50% readout ~2029-01-29 | Phase 3 | INCB123667, Investigator's choice of chemotherapy | Ovarian Cancer | — | recruiting |
| 2028-12-29 Estimated 50% readout ~2029-03-14 | Phase 3 | INCA33890, Bevacizumab, FOLFOX | CRC (Colorectal Cancer) | — | recruiting |
| 2029-01-31 Estimated 50% readout ~2029-03-17 | Phase 2 | INCA034176, Best available Treatment (BAT) | Chronic Graft-versus-host-disease | — | recruiting |
| 2029-06-15 Estimated 50% readout ~2029-08-29 | Phase 3 | INCA033989, Best Available Treatment | Essential Thrombocythemia | — | not yet recruiting |
| 2030-05-24 Estimated 50% readout ~2030-06-23 | Phase 1 | INCA036978, Standard disease-directed therapy | Myeloproliferative Neoplasms | — | recruiting |
| 2031-01-17 Estimated 50% readout ~2031-04-02 | Phase 3 | Tacrolimus (Tac), Methotrexate (MTX), Ruxolitinib (Rux) | Graft-versus-host Disease (GVHD) | — | recruiting |
| 2026-07-22 Estimated 50% readout ~2026-09-05 final ~2027-07-31 | Phase 2 | INCB099280 | Advanced Solid Tumor | — | active not recruiting |
| 2026-07-13 Estimated 50% readout ~2026-09-26 final ~2027-07-31 | Phase 3 | Ruxolitinib, Vehicle Cream | Atopic Dermatitis | — | active not recruiting |
| 2026-03-03 | Phase 2 | Ruxolitinib, Asparaginase Erwinia Chrysanthemi, Cyclophosphamide, Cytarabine, Dexamethasone | Leukemia | 171 | completed |
| 2025-09-29 | Phase 1 | INCB161734, Itraconazole, Rifampin, Esomeprazole, Famotidine | Healthy Participants | 63 | completed |
| 2025-07-07 | Phase 3 | Pemigatinib, Gemcitabine, Cisplatin | Unresectable Cholangiocarcinoma, Metastatic Cholangiocarcinoma | 167 | terminated |
| 2025-05-21 | Phase 3 | Ruxolitinib Cream, Vehicle Cream | Atopic Dermatitis | 241 | completed |
Catalyst news & presentations · 6
- 2026-07-28Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-07-06partnershipVGA039 · Incyte completed acquisition of Vega Therapeutics for $1.25B upfront plus up to $750M milestones.SEC 8-K
- 2026-06-22fda agreementOpzelura · Agreement with CMS that line extension regulation will not apply to Opzelura; lawsuit withdrawn.SEC 8-K
- 2026-06-08partnershipIncyte enters definitive agreement to acquire Vega Therapeutics.SEC 8-K
- 2026-04-02partnershipADG126 and INCA33890 · Clinical collaboration to evaluate ADG126 in combination with INCA33890 in MSS CRC.PR wire
- 2026-02-27crlZynyz · CRL issued due to inspection findings at Catalent Indiana facility; no efficacy or safety concernsSEC 8-K
Approved drugs (6)
- JAKAFI XRRUXOLITINIB PHOSPHATE2026 · Prescription
- NIKTIMVOaxatilimab-csfr2024 · Prescription
- ZYNYZRETIFANLIMAB-DLWR2023 · Prescription
- OPZELURARUXOLITINIB PHOSPHATE2021 · Prescription
- PEMAZYREPEMIGATINIB2020 · Prescription
- JAKAFIRUXOLITINIB PHOSPHATE2011 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $114 (-1% upside) · 22 analysts
- 2026-07-21HC Wainwright & Co.Buy
- 2026-07-14BarclaysOverweight
- 2026-07-13BMO CapitalMarket Perform
- 2026-07-07RBC CapitalSector Perform
- 2026-06-29HC Wainwright & Co.Buy
- 2026-06-26UBSNeutral
Competitors — Solid Tumors
- ABBVAbbVie Inc.$451.1B · D2
- NVSEFNOVARTIS AG$292.0B · D3
- ERASErasca, Inc.$5.9B · D4
- CELG-RIBRISTOL MYERS SQUIBB CO$241M · D2
- CRBPCorbus Pharmaceuticals Holdings, Inc.$164M · D7
- BCYCBICYCLE THERAPEUTICS PLC$124M · D4
- XLOXilio Therapeutics, Inc.$50M · D1
- NXTCNextCure, Inc.$16M · D9
- APREAprea Therapeutics, Inc.$8M · D6
Recent news
- 2026-07-23Incyte stock trades steadily as Jakafi revenue supports oncology pipeline - Ad-hoc-news.de
- 2026-07-21Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
- 2026-07-21H.C. Wainwright reiterates Incyte stock rating on Halozyme deal - Investing.com
- 2026-07-21Incyte stock trades steady as recent revenue growth and Jakafi franchise metrics shape investor focu - Ad-hoc-news.de
- 2026-07-20Incyte Corp. stock underperforms Monday when compared to competitors - MarketWatch
- 2026-07-20Incyte EVP, Head of U.S. Commercial Issa Mohamed Khairie sells 1,093 shares for $125,705.93 - Bitget
- 2026-07-20Incyte Corp (INCY) grants RSUs and stock options to accounting chief - Stock Titan
- 2026-07-20Incyte Corp (INCY) CMO awarded RSUs, options and sells stock - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.